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Summary We recentty reported that rhabdomyosarcoma cell lines express and secrete interleukin 15 (IL-15), a tightty regulated cytokine
with IL-2-like actvity. To test whether the p53-impaired function that is frequently found in this tunour type could play a role in the IL-15
producbon, wild-type p53gene was transduced in the human rhabdomyosarcoma cell line RD (which harbours a mutated p53gene), and its
effect on proliferation and expression of IL-15 was studied. Arrest of proliferation was induced by wild-type p53: increased proporions of G1-
arrested cells and of apoptotic cells were observed. A marked down-modulatin of IL-15 expression, at both the mRNA and protein level, was
found in p53-transduced cells. Because a direct effect of IL-15 on norrnal muscle cells has been reported, the presence of IL-15 membrane
receptors was studied by cytofluorometnc analysis. Rhabdomyosarcoma cells showed IL-15 membrane receptors, which are down-
modulated by wild-type p53 transfected gene. In conclusion, wild-type p53 transductn in human rhabdomyosarcoma cells induces the
down-modulation of both IL-15 production and IL-15 receptor expression.
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Mutation in the tumour-suppressor gene p53 is the most frequent
alteration found in human tumours (Ko and Prives. 1996). Wild-
type p53 is a transcription and translation regulator acting on a
variety of genes involved in the control ofcell cycle and differen-
tiation (Ewen and Miller. 1996; Bourdon et al. 1997) that can be
either activated or repressed. These genes include cytokines and
growth factors (Fujiwara et al. 1994; Shin et al. 1995: Pesch et al.
1996: Zhang et al. 19%). Therefore. impairedp53 function could
determine a deregulated production of cytokines/growth factors.
which could be of advantage for the malignant phenotype
(Baserga. 1994). Rhabdomyosarcoma. the most frequent soft-
tissue sarcoma in childhood (Pappo et al. 1995). frequently shows
impaired p53 function (Felix et al. 1992: Diller et al. 1995: Keleti
et al. 1996) and produces a variety ofgrowth factors (Schweigerer
et al. 1987; El-Badry et al. 1990: De Giovanni et al. 1995) that
could be subject to transcription control by p53 (Fujiwara et al.
1994: Shin et al. 1995: Zhang et al. 1996). We recently found that
rhabdomyosarcoma cell lines express and secrete interleukin 15
(IL-15) (Lollini et al. 1997). This cytokine. controlled at both tran-
scription andtranslation levels. has an IL-2-like activity (Tagaya et
al. 1996; Onu et al. 1997) and protects from apoptosis both in vitro
and in vivo (Bulfone-Paus et al. 1997). IL-15 transcription has
been found in a variety ofnormal and neoplastic tissues (Grabstein
et al. 1994: Tagaya et al. 1996). but secretion of IL-15 protein is
restricted to some normal cell types and a few neoplastic cell lines.
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including rhabdomyosarcoma (Lollini et al. 1997). To test whether
impaired p53 function could play a role in IL-15 production. we
transfected p53 gene in rhabdomyosarcoma cells and studied the
effects on proliferation and on IL-15 transcription and production.
Because cells of the muscle lineage can respond to exogenous
IL-15 (Quinn et al. 1995). expression of IL-15 receptors was also
studied.
MATERIALS AND METHODS
Cells and p53gene transduction
Transduction of p53 gene was perforned in the human rhabdo-
myosarcoma cell line RD. which is known to harbour a mutation in
codon 248 of the p53 gene (Felix et al. 1992). Unless otherwise
specified, cells were cultured in Dulbecco's modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) at 370C in a humidified 7% carbon dioxide atmosphere. All
media constituents were purchased from Life Technologies. Milan.
Italy. Plasmid pN53cG(Val-135). carrying the temperature-sensi-
tivep53 (ial-135) gene (ts-pS3) under the control ofHaMSV-LTR
and the selectable marker neo under the control of the RSV-LTR
(Soddu et al. 1994). and plasmid pRSVneo, carrying the selectable
marker alone. were used for transfections. Approximately 3 x 106
exponentially growing RD rhabdomyosarcoma cells were trans-
fected by electroporation (0.25 V. 960jiF) with a gene pulser (Bio-
Rad Laboratonres. Hercules. CA. USA). Transfectants were cloned
by limiting dilution in medium containing 0.75 mg mll G418
(Gibco BRL): one clone designated RD-tsp53 and one control
designated RD-Neo were then studied. All transduced cells were
routinely cultured at 37°C and shifted to the permissive tempera-
ture of32°C forexperimental studies.
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To verify the transactivating action ofts-p53 gene product at the
two culture temperatures, RD-Neo and RD-tsp53 transfectants
were retransfected with a chloramphenicol acetyltransferase
(CAT) reporter construct. Approximately 1 x 105 cells were plated
in 60-mm dishes and transfected by calcium phosphate precipita-
tion with PG 3CAT vector, carrying the CAT reporter gene driven
by a polyomavirus promoter and 13 copies ofthe p53 consensus-
binding sequence, orMG,5CAT vector with 15 copies ofp53 non-
binding sites (Kem et al, 1992) (kindly provided by B Vogelstein).
Soon after transfection, the cells were trypsinized and seeded in
two new dishes, one of which was incubated at the permissive
temperature andthe otherat the non-permissive temperature. After
48 h, the cells were lysed by freeze and thaw. CAT activity was
determined using the two-phase fluorescence diffusion assay as
described previously (Huffet al, 1993); counts per minute (c.p.m.)
were normalized to protein quantity.
Overexpression ofwild-typep53 was also obtained by infection
of RD cells with replication-defective, recombinant adenovirus
carrying the human wild-type p53 cDNA (AdJL16), kindly
provided by Silvia Bacchetti (Bacchetti and Graham, 1993).
Adherent RD cells were infected with 20 p.f.u. ofAd-p53 ord1312
control adenovinus, as described previously (Bacchetti and
Graham, 1993). Forty-eight hours later, cells were subjected to
reverse transcnptase polymerase chain reaction (RT-PCR) analysis.
Proliferation studies
RD-tsp53 and RD-Neo cells were seeded in DMEM + 10% FBS at
the density of 10 cells cm-2 and cultured at 37°C or 32°C for 4
days, then cultures were switched to a medium with a low content
of exogenous growth factors (DMEM + 2% horse serum) and
incubation continued for further 7 days with medium renewal
every 2-3 days. At 3-4 day intervals, cultures were harvested and
cell number and viability were determined by trypan blue dye
exclusion test.
Forcell cycle analysis, 5 x 10 trypsinized cells were washed in
PBS, fixed in cold methanol-acetone (1:4) solution for 30 mm at
4°C and DNA was stained with 50 ig ml' propidium iodide
(Sigma, St. Louis, MO, USA) in phosphate-buffered saline (PBS)
with 2 jg ml-' RNAase A (Boehringer-Mannheim Italia, Milan,
Italy) for 30 min at room temperature. The content of DNA was
measured by an Epics XL analyser (Coulter Corporation, Miami.
FL, USA).
The proportion of apoptotic cells was studied on cells cultured
as above, harvested and stained with Hoechst 33342; about 500
cells were scored for apoptotic bodies at 40x magnification.
In some experiments, cell cultures were treated with exogenous
recombinant human IL-15 (Immunex, Seattle, WA, USA) at
concentrations ranging from 100 to 1000 ng ml-, with anti-IL-15
monoclonal antibody M 11 (Immunex), at a final concentration of
3 jig ml-', or with anti-IL-15 polyclonal antibody (PeproTech,
London, UK), at a final concentration of 5 jig ml-'; cell yield was
determined 4 days later.
IL-15expression
Cells transduced and cultured as above were utilized for RNA
extraction, cDNA synthesis and RT-PCR, as reported previously
(De Giovanni et al, 1995; Lollini et al, 1997). RNA was extracted
from at least three independent experinments in which control and
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thepermss tenrerature of 32°C. RD-Neo- and RD-tspb3-transfected
cells were rebtansected with PG,3CAT vector, carrying the CAT reporter gene
driven by polyofafirus profoter and 13 copes of the p53 consensus-
bdg sequence or with the control MG,CATvectorwih 15 copies of a p53
non-biding site. CATacivity (see Materials and methods) in cels cuitured at
320C is shown
p53 transfectants were run in parallel; a cDNA panel from each
expernment was tested in RT-PCR at least twice. Specific primer
pairs for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and transforming growth factor 0, (TGF-3,) were obtained from
Clontech (Palo Alto, CA. USA); prinmers for IL-15 were synthe-
sized as reported previously (Lollini et al, 1997).
Enzyme-inked immunosorbent assay (EUSA)
Cells were seeded at a concentration of 4-8 x 104 cells cm-2 and
cultured at 37°C or 32°C. After 4 days, cultures were switched to
RPMI +0.5% FBS and incubationcontinued forafurther4 days at
37°C or at 32°C respectively. Cell supematants were then
collected and IL-15 and TGF-01 prduction measured by means
of ELISA purchased from Genzyme (Milan, Italy) and used
according to the manufacturer's protocol. Supernatants for IL-15
determination were concentrated about 100 times as reported
previously (Lollini et al. 1997). At the same time, cell cultures
were harvested and cell yield was determined. Cytokine produc-
tion was expressed in pg per 106 cells.
Cytofluorometic sdies
Expression of membrane molecules on cells seeded at 106 cells
cm-2 and cultured at 37°C or 32°C was detrmined by indirect
immunofluorescence and cytofluorometric analysis (FACScan,
Becton Dickinson, Mountain View. CA, USA) using the following
primary reagents: IL-15-IgG2b fusion protein, which recognizes
all membrane IL-15 binding sites, produced by cells trsduced
with a human IL-15-murine IgG2b fusion construct (Bulfone-Paus
et al, 1997); monoclonal antibody M160 (Immunex) recognizing
the a-chain of the trimeric IL-15 receptor, polyclonal C-16 anti-
serum (Santa Cruz Biotechnology, Santa Crz, CA, USA) recog-
nizing TGF->-Rll; anti-human class I major histocompatibility
complex W6/32 antibody (SeraLab, Crowley Down, UK): anti-
CD44 monoclonal antibody. clone IM7 (PharMingen. San Diego.
Britsh Joumal ofCancer(1998) 78(12), 1541-1546
4p 4pie Iq I(F
0 CancerResearch Campaign 1998Wild-type p53-mediatedmodulation ofIL-15 and IL-15 receptors 1543
A
, RD-Neo
RD-tsp3
a,.-
//
/y XRD-Neo
//
/i X
3TC
37°C 32°C Adeno
L0 to
a 0 %-
Z t
Z 0 0 in
' cj 0
cc cc cc EC IT 3:
IL-15 -
TGF_
GAPDH
3 6 9 12
Days of culture
Fhgure 2 Proliferation of ts-p53 gene tansduced RD human
rhbdmyosarna cells cultured at 37°C (mutated p53 conformation) and at
32°C (wiklype p53 conotion). Open symbols, RD-Ne transfectnt
cells; closed sytbols, RD-tsp53 tasea cels; dashed ine, 37°C;
continuous line, 32°C
CA, USA). The results shown are from an experiment representa-
tive of at least two independent experiments. To study the expres-
sion of p53, the monoclonal antibody PAbl22 (Boehringer
Mannheim, Germany) recognizing both wild-type and mutatedp53
was used in indirect immunofluorescence on cells fLxed with
methanol.
RESULTS
Human rhabdomyosarcoma cells RD were wansduced with the ts-
p53 gene, whose product behaves like wild-type p53 at the pennis-
sive temperature of320C (Soddu et al, 1994). p53 expression level
and transactivating action at both permissive and non-pennissive
temperatures were determined on transfectant cells. A high p53
expression was observed by cytofluorometry in RD-tsp53 trans-
duced cells at both temperatures by means ofan antibody thatbinds
to p53 in the wild type as well as in the mutated conformation (data
not shown). To verify the ransactivating action of ts-p53 gene
product, RD-Neo and RD-tsp53 transfectants were retransfected
with PG3CAT vector, carrying the CAT reporter gene driven by
polyomavirus promoter and 13 copies of the p53 consensus-
binding sequence or withMG,5CAT vector with 15 copies of a p53
non-binding site (Kern et al, 1992). Baseline levels ofCAT activity
were observed in all transfectants cultured at the non-permissive
temperature (data not shown), whereas a very high ability to trans-
activate PG13 driven CAT expression was observed in RD-tspS3
cells cultured at the permissive temperature (Figure 1).
In RD-tsp53 transfectants, the induction of wild-type p53
conformation by culture at 32°C caused an almost complete arrest
ofcell growth (Figure 2); the same cells cultured at 37°C showed a
growth rate close to that of RD-Neo transfectant control cells.
Proportions of G, cells and of apoptotic cells were studied as
potential causes of growth arrest induced by wild-type p53. The
proportion ofG, cells in RD-tsp53 transfectants cultured at 32°C
showed a twofold increase over that ofRD-Neo controls (72% and
36%, respectively) and a twofold increase in the proportion of
apoptotic cells was also observed (3.9 ± 0.2% and 2.2 ± 0.2%
respectively).
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Figure 3 Productionof IL-15 and TGF-1 by p53 gene bansduced RD cels.
(A) Expression of mRNA for IL-15,TGF-P, and GAPDH evaluated by RT-
PCR. RNA was extacted from RD-Neo and RD-tsp53 transfectant cultures
incbated 4 days at the iricated teperature and from adenovifected
cultures 48 h after infection. For each RT-PCR produd the foling
ampnlficto cycles are shown to compare control and p53transfeant
samples in the exponential ampifica phase: IL-15, 30; TGF-O, 25;
GAPDH, 20. (B) IL-15 andTGF-P, release in sqermnaants by RD-Neo and
RD-tsp53 tansduced cells cultured at 37°C or at 32WC
The expression of mRNA for IL-15 was studied by RT-PCR in
comparison with the expression of an unrelated growth factor
(TGF-j1) and of a housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Figure 3A). For each primer pair, the
comparisonbetweencDNAs derived from RD-Neo- and RD-tsp53-
transfected cells was made in the exponential amplification phase.
GAPDH showed that comparable cDNAs were obtained: PCR
products of similar intensity were always observed after 15-25
amplification cycles. A down-modulation of IL-15 tanscript was
observed in RD-tsp53-transfected cells at 370C and at 320C (Figure
3A). The mean decrease in the intensity of ethidium bromide-
stained bands, evaluated by densitometric analysis offive indepen-
dent experiments, was: 38.4% ± 8.6 at 370C and 71.0% ± 7.3 at
32°C. Therefore, p53 down-modulation of 1L-15 was significantly
higher (P = 0.016) in the wild-type confonnation. Down-modula-
tion of the IL-15 transcript was constantly observed at different
time points (e.g. from 2 to 12 days) aftercell seeding.
The expression ofwild-type p53 protein was also induced in RD
cells by infection with an adenovirus vector. again a decrease in
the ]11-15 RT-PCR product was observed in Ad-p53 infected cells
in comparison with cells infected with the control adenoviral
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Fgure 4 Cytofluorotic analyss of membrane receptors for IL-15 and
TGF-1 in RD-Neo and RD-tsp53 transduced cells cultured at 370C or at
32°C. In each graph, the abscissa represents fluorescence intensity on a
kogarithmic scale ranging from 10° to 10', and the ordinate represents the
number of cells. Open profiles, cells stained with secondary antbody alone;
shaded profiles, cells stained with antbody or fusion protein recognizing the
indicated specficity
vector (Figure 3A). Mean decrease ± s.e. from three expenrments
was 55.0% ± 14.0.
Down-modulation of IL-15 mRNA was not due to an unspecifi-
cally decreased transcription activity because the expression of
TGF-01 (Figure 3A) was slightly increased.
Post-transcriptional regulation of IL-15 protein production has
been reported (Tagaya et al. 1996; Onu et al, 1997). Therefore, the
expression of secreted IL-15 protein was studied by an ELISA in
supematants from RD-Neo and RD-tsp53 transfected cells (Figure
3B). A strong decrease in IL-15 production was already observed
in RD-tsp53-transfected cells cultured at 370C and reached 90%
reduction in 32°C cultures. This decrease is unlikely to be due to a
non-specific decrease in metabolic activity because the production
of TGF-13, whose baseline level was approximately 200-fold
higher than that of IL-15. was actually increased under the same
experimental conditions (Figure 3B).
IL-15 binds to a membrane trimeric receptor. composed of a
specific a-chain (IL-15Ra) and of>- and y-chains shared with other
interleukins. Moreover, an unknown receptor has also been reported
on mast cells (Tagaya et al. 1996). The presence of IL-15 receptors
on p53-transduced RD cells was studied by means of cytofluori-
metry. either using a monoclonal antibody recognizing IL-15Ra or
the IL-15-IgG2b fusion protein (Bulfone-Paus et al. 1997) that
detects cell membrane binding sites. RD-Neo cells expressed IL-15
membrane receptors. as shown by the binding ofthe fusion protein.
and at least part of the binding was due to the presence of IL-l5Ra
(Figure 4). Down-modulation ofboth total IL-15 membrane binding
and of IL-15Ra was observed in RD-tsp53-transfected cells when
the wild-type p53 conformation was induced by culture at 32°C. No
difference was observed forTGF_j-RHg (Figure 4).
The treatment of RD-Neo and RD-tsp53 cells with exogenous
recombinant human IL-15 at concentrations up to 1000 ng ml-'. as
well as with either monoclonal or polyclonal anti-IL-15 anti-
bodies, did not determine any change in cell proliferation and in
expression of membrane glycoproteins such as HLA-A. B. C and
CD44 (data not shown).
DISCUSSION
Human rhabdomyosarcoma cell line RD was transduced with p53
gene using two different vector systems: a ts-p53 plasmid (Soddu
et al. 1994). giving rise to stable transfectants in which wild-type
p53 conformation is dependent upon the culture temperature. and
an adenoviral vector carrying the wild-type p53 gene (Bacchetti
and Graham. 1993). in which a high transient wild-type p53 gene
expression could be studied within a few days after infection. With
both vector systems a down-modulation of IL-15 transcription was
observed. This was not due to an unspecific decrease in transcrip-
tion activity because expression of an unrelated growth factor
(TGF-,B1) was slightly increased.
In the ts-p53 system. down-modulations ofIL-15 transcription and
production were also observed at the non-pennissive culture temper-
ature. but the effect was significantly higher when the wild-type
conformation was induced The effect of ts-p53 at 37°C could be
related to its leakiness leading to a low amount of p53 in the wild-
type conformation even at this temperature. However. experiments
performed at a higher temperature (390C) confirmed that the
decrease in IL-15 production was already observed with ts-p53 in the
mutated conformation (data not shown). This suggests that both
mutated and wild-type p53 were active in down-modulating IL-15. A
similar phenomenon has been reported for other cytokines in expen-
mental models based on p53 mutants. e.g. IL-2 and IL4 are down-
modulated by wild-type p53 as well as by deletion mutant p53 (Pesch
et al. 1996). TGF-j31 production was reported to be increased by both
wild-type and mutated p53 in a glioblastoma cell line (Fujiwara et al.
1994): this finding was extended to rhabdomyosarcoma by the
present study with temperature-sensitive p53 gene products.
Although the above-mentioned IL-15 down-modulation was
induced by both wild-type and mutated p53. other effects reported
here were specific for p53 in the wild-type conformation. such as
the growth arrest and the down-modulation of IL-15 receptors.
These different behaviours could suggest that different mecha-
nisms ofp53 action are involved.
The presence of two p53 consensus sequences (the decamer
PuPuPuCAf[T/APyPyPy) in the promoter and/or intronic regions
oftransactivated genes is a mechanism for p53 action as transcrip-
tion factor (Bourdon et al. 1997). IL-15 promoter has not yet been
studied. but a p53 consensus sequence is present in the first intron
of the IL-15 gene (GAACTGGCCT. position 18-27 of the
sequence X91233 ofGenBank).
An altemative to p53 consensus sequence binding. a 'non-
specific' mechanism based on p53 protein interaction with general
transcription factors (Ko and Prives. 1996). has been hypothesized
for p53-induced down-modulation of IL-2 and IL-4 (Pesch et al.
1996). IL-15 could share this mechanism with other interleukins.
It must be remembered that IL-2 and IL-15 share receptors and
activities (Grabstein et al. 1994; Tagaya et al. 1996).
Different p53 properties are related to different protein domains
(Ko and Prives. 1996). The ts-p53 gene we transfected harbours
the temperature-sensitive Val-135 mutation in the DNA-binding
central core region: alterations in this domain are responsible for
properties of p53 leading to increased tumorigenic potential of
cells resulting from changes in the ability to bind DNA. Val-135-
mutated p53. however, could maintain, at least in part the ability
to interact with general transcription factors through the amino-
terminal domain. and this could lead to the transcription modula-
tion by mutated p53 found for some cytokines (IL-2/4 and IL-15)
(Pesch et al. 1996. present study).
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It is also possible that some of the reported effects may be
related to the state ofthe cell cycle machinery. not directly via p53
protein-protein interactions. The study of p21 --FI. a key down-
stream effector of p53 inhibition of cell cycle, will help in clari-
fying which mechanism is involved in different effects. P211lF'
transfection (Meng et al. 1998) as well as treatment with exoge-
nous p2l--'F peptides (Ball et al. 1996) could mimic p53 gene
effects related to the state ofcell cycle machinery. If p21w-F does
not mimic p53 effects. then it is more likely that the mechanism is
related directly to p53 non-specific suppression oftranscnrption.
A few IL-15 transcription modulators [e.g. UV radiations and y-
interferon (IFN-y)] which lead to an up-modulation in normal cells
are known so far (Tagaya et al. 1996). Wild-type p53 leads to a
decreased transcription: this is the first example of a down-
modulation of IL-15.
The study ofproliferative ability ofstable RD-tsp53 transfectants
showed that whereas at non-permissive temperature RD-tspS3-
transduced cells had a growth curve close to RD-Neo control.
expression ofp53 in the wild-type conformation led to an almost
complete arrest of growth that could be determined by increase in
GI arrest and in apoptosis rate. IL-15 protects from apoptosis both
in vitro and in vivo (Bulfone-Paus et al. 1997). Therefore. IL-15
and p53 appear to exert antagonistic roles on cell apoptosis rate.
IL-15 produced by rhabdomyosarcoma cells could act in a
paracrine way in the tumour microenvironment. interacting with
cells expressing IL-15 receptors. such as lymphocytes and mast
cells. but at present it is not known whether and how this cytokine
modifies the tumour-host relationship. Moreover. IL-15 has been
reported to promote angiogenesis in vivo (Angiolillo et al. 1997). a
phenomenon that is becoming more and more relevant for malig-
nancy. IL-15 release in culture medium by rhabdomyosarcoma
cells reached very low levels. ofthe order of5-10 pg ml-' (present
data and Lollini et al. 1997). These levels are apparently lower
than the threshold (about 25 pg mn-') required for in vitro lympho-
cyte proliferative responses (Grabstein et al. 1994: our unpub-
lished data). but in the local in vivo microenvironment short-range
acting cytokines could have significant effects even at low concen-
trations. In particular. for IL-15 it has been suggested that receptor-
positive cells able to release the cytokine could store a high
concentration of IL-15 molecules on their surface. ready to be
presented to passenger cells (Meazza et al. 1997).
The possibility that IL-15 also acts in an autocrine way must be
considered because RD rhabdomyosarcoma cells display both the
specific a-chain of the trimeric receptor and IL-15 membrane
binding, sites. as shown by the IL-15-IgG2b fusion protein. Some
data on the effectiveness of IL-15 in muscle cells have been
reported (Quinn et al. 1995). We are currently studying whether
autocnne effects (such as induction of proliferation or modifica-
tions in the expression ofmembrane molecules) are determined by
IL-15 in rhabdomyosarcoma cells. However. in vitro treatment of
rhabdomyosarcoma cells with exogenous recombinant IL-5 or
with monoclonal and polyclonal anti-IL-15 neutralizing antibodies
did not determine any modification in cell proliferation and in
expression of membrane glycoproteins such as HLA-A. B. C and
CD44. This is in accordance with the absence of proliferating
effects observed in normal muscle cells (Quinn et al. 1995).
In conclusion. a selective down-modulation of both IL-15 and
IL-15 receptors was found in rhabdomyosarcoma cells transduced
with wild-typep53. This indicates acontrol ofIL-15 circuits by p53
and suggests that further efforts should be directed to the study of
the role of IL-15S in the progression of human rhabdomyosarcoma.
NOTE ADDED IN PROOF
The recent availability of the IL-15 promoter sequence (reported
by Azimi et al. 1998. Proc NatlAcad Sci USA 95: 2452) prompted
us to reanalyse all available IL-15 sequences for p53 consensus
binding sites. No consensus sequence was found in the IL-15
promoter. whereas several clusters of one. two and four decamers
(with 0. 2 and 4 mismatch tolerance respectively) were found in
introns 3. 4 and 5 and in the last exon (GenBank X91233).
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